PMID- 6231095
OWN - NLM
STAT- MEDLINE
DCOM- 19840518
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 16
IP  - 3
DP  - 1984
TI  - Gamma-irradiation facilitates the expression of adoptive immunity against 
      established tumors by eliminating suppressor T cells.
PG  - 175-81
AB  - It was found that sublethal (550 rad) whole-body gamma-irradiation of mice 
      bearing established immunogenic tumors enabled tumor-sensitized spleen cells 
      infused intravenously 1 h later to cause complete tumor regression in all mice. 
      In contrast, gamma-irradiation alone caused only a temporary halt in tumor 
      growth, and immune cells gave practically no therapeutic effect at all. This 
      result was obtained with the SA1 sarcoma, Meth A fibrosarcoma, P815 mastocytoma, 
      and P388 lymphoma. Additional experiments with the Meth A fibrosarcoma revealed 
      that the spleen cells from tumor-immune donors that caused tumor regression in 
      gamma-irradiated recipients were T cells, as evidenced by their functional 
      elimination by treatment with anti-Thy-1.2 antibody and complement. It was shown 
      next that adoptive T-cell-mediated regression of tumors in gamma-irradiated 
      recipients was inhibited by an intravenous infusion of spleen cells from donors 
      with established tumors, but not by spleen cells from normal donors. The spleen 
      cells that suppressed the expression of adoptive immunity were functionally 
      eliminated by treatment with anti-Thy-1.2 antibody and complement. Moreover, they 
      were destroyed by exposing the tumor-bearing donors to 500 rad of gamma-radiation 
      24 h before harvesting their spleen cells. The results are consistent with the 
      interpretation that gamma-radiation facilitates the expression of adoptive 
      T-cell-mediated immunity against established tumors by eliminating a population 
      of tumor-induced suppressor T cells from the tumor-bearing recipient.
FAU - North, R J
AU  - North RJ
LA  - eng
GR  - CA-16642/CA/NCI NIH HHS/United States
GR  - CA-27794/CA/NCI NIH HHS/United States
GR  - RR-05705/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Isoantibodies)
RN  - 0 (anti-Thy antibody)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Animals
MH  - Complement System Proteins
MH  - Gamma Rays
MH  - Germ-Free Life
MH  - *Immunization, Passive
MH  - Isoantibodies
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Neoplasms, Experimental/*immunology
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Whole-Body Irradiation
PMC - PMC11039020
EDAT- 1984/01/01 00:00
MHDA- 1984/01/01 00:01
PMCR- 1984/03/01
CRDT- 1984/01/01 00:00
PHST- 1984/01/01 00:00 [pubmed]
PHST- 1984/01/01 00:01 [medline]
PHST- 1984/01/01 00:00 [entrez]
PHST- 1984/03/01 00:00 [pmc-release]
AID - BF00205425 [pii]
AID - 10.1007/BF00205425 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 1984;16(3):175-81. doi: 10.1007/BF00205425.